Within a cohort comprising 154 patients with locally advanced NSCLC, who were administered second-line or later-line anti-PD-1 therapy, the ECOG score, smoking history, liver metastasis, LDH, and NLR demonstrated significant associations with both PFS and OS. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.